1694MO Novel serum glycoproteomic biomarkers predict response to nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in advanced RCC (aRCC): Analysis from CheckMate 9ER
Braun D, Wang Y, Yu A, Pickering C, Serie D, Choueiri T, Xu W, Sun M, Vemula S, Gupta S. 1694MO Novel serum glycoproteomic biomarkers predict response to nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in advanced RCC (aRCC): Analysis from CheckMate 9ER. Annals Of Oncology 2024, 35: s1012-s1013. DOI: 10.1016/j.annonc.2024.08.1787.Peer-Reviewed Original ResearchAdvanced RCCResponse to nivolumab